RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Royalty Pharma plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$60.27−0.69 (-1.13%)
Close on Oct 19, 2026
- Market cap
- $33.56B
- P/E (TTM)
- 34.2
- Dividend yield
- –
Royalty Pharma plc revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Income from financial royalty assets | $2.26B | $2.15B | $2.20B | $2.13B | $2.07B | $1.96B | $1.65B | $1.52B | 95.1% | +5.2% |
| Other royalty income and revenues | $117.04M | $114.15M | $156.80M | $112.12M | $53.13M | $19.00M | $19.64M | $135.96M | 4.9% | +2.5% |
| Revenue from intangible royalty assets | – | – | $835.00K | $37.48M | $171.25M | $143.38M | $145.78M | $134.12M | – | – |
By region
From the segment and revenue-disaggregation notes of Royalty Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.